Early Bayesian Dose Adjustment of Vancomycin Continuous Infusion in Children in a Randomized Controlled Trial | Zendy

Romain Berthaud | Zendy; Sihem Benaboud | Zendy; Déborah Hirt | Zendy; Mathieu Genuini | Zendy; Mehdi Oualha | Zendy; Martin Castelle | Zendy; Coralie Briand | Zendy; S. Artru | Zendy; Lorenzo Norsa | Zendy; Olivia Boyer | Zendy; Frantz Foissac | Zendy; Naïm Bouazza | Zendy; JeanMarc Tréluyer | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Early Bayesian Dose Adjustment of Vancomycin Continuous Infusion in Children in a Randomized Controlled Trial

Author(s) -

Romain Berthaud,

Sihem Benaboud,

Déborah Hirt,

Mathieu Genuini,

Mehdi Oualha,

Martin Castelle,

Coralie Briand,

S. Artru,

Lorenzo Norsa,

Olivia Boyer,

Frantz Foissac,

Naïm Bouazza,

JeanMarc Tréluyer

Publication year - 2019

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01102-19

Subject(s) - vancomycin , medicine , randomized controlled trial , therapeutic drug monitoring , pharmacokinetics , therapeutic index , pediatrics , drug , pharmacology , staphylococcus aureus , biology , bacteria , genetics

Methicillin-resistant staphylococcal infections are a global burden. Area under the concentration-time curve to MIC (AUC/MIC) ratio is the pharmacokinetic (PK) parameter that best predicts vancomycin efficacy. Its therapeutic range is narrow, difficult to achieve because of a wide intersubject variability, especially in children, and is not routinely targeted since the AUC is rarely available.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research